Department of Pathology, The Second People’s Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Changzhou, China
Auto-generated profile, based on publicly available information
Yang Zhou
Department of Pathology, The Second People’s Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Changzhou, China
KRASG12D, the most common oncogenic KRAS mutation, is a promising target for the treatment of pancreatic cancer. Herein, we identified four potent and noncovalent KRASG12D inhibitors (hits 1–4) by using structure-based virtual screening and biological evaluation. The in vitro assays indicated that the four compounds had sub-nanomolar affinities for KRASG12D and showed a dose-dependent inhibitory effect on human pancreatic cancer cells. In particular, the hit compound 3 was the most promising candidate and significantly inhibited the tumor growth of pancreatic cancer in tumor-bearing mice. The hit compound 3 represented a promising starting point for structural optimization in hit-to-lead development. This study shows that hit compound 3 provides a basis for the development of the treatment of cancer driven by KRASG12D.
15 May 2025 in European Journal of Medicinal Chemistry
Cancer is one of the important factors threatening human health. Hence, it is essential to create novel potent drugs to treat it. Due to the strong correlation among histone deacetylase1 (HDAC1), speckle-type POZ protein (SPOP) and cancers, dual inhibition of HDAC1 and SPOP may be a promising strategy for cancer treatment. In this study, we successfully identified four potential dual-targeting HDAC1/SPOP candidate compounds with structure-based virtual screening. In vitro inhibition experiments confirmed that the four compounds had dual inhibitory effects on HDAC1 and SPOP. Among them, compound HS-2 had a stronger inhibitory effect on HDAC1 and SPOP than the positive controls. Further molecular dynamics simulations indicated that HS-2 could stably bind to HDAC1 and SPOP. In addition, MTT assay indicated that HS-2 inhibited the growth of tumor cells in the micromolar range. In vivo evaluation showed that HS-2 could obviously inhibit the growth of tumor in nude mice without obvious toxicity. These findings suggest that HS-2 is a novel and potent dual-targeting HDAC1/SPOP inhibitor for cancer treatment.
25 February 2025 in European Journal of Medicinal Chemistry
Accurate preoperative assessment of central lymph node metastasis (CLNM) in papillary thyroid carcinoma (PTC) remains challenging. This retrospective study was registered at ClinicalTrials.gov (NCT06725628) on December 9, 2024. A total of 934 patients with confirmed PTC who underwent cervical central lymph node dissection between January 2023 and December 2024 were included. Radiomics features were extracted and selected. Deep learning models were trained and used for automatic segmentation and classification. We developed and validated a Thy-CLNM Fusion model, which achieved an AUC of 0.862, with a sensitivity of 78.9% and a specificity of 79.3% in the validation cohort. We compared the proposed model with other models that also predict CLNM, and the results demonstrated competitive performance compared with previously reported models. Histopathological slides from 231 patients were retrospectively reviewed to provide pathological interpretability. In the CLNM low-risk group, model activation predominantly localized to hyperechoic Habitat I regions, corresponding pathologically to fibrous hyperplasia and active lymphocyte–tumor cell interactions. In the CLNM high-risk group, model attention showed dominant localization in hypoechoic Habitat II regions, which were associated with nuclear atypia, poor differentiation, reduced intercellular adhesion, and vascular invasion. The proposed model offers an additional preoperative decision-support option for CLNM risk assessment in PTC patients who are planning to undergo surgery and are being considered for central lymph node dissection.